Tacrine–Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties
María Isabel Fernández‐Bachiller(Medicina), Marı́a Isabel Rodrı́guez-Franco(Instituto de Química Médica), Gema C. González-Muñoz(Consejo Superior de Investigaciones Científicas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Mércedes Villarroya(Universidad Autónoma de Madrid), Manuela G. López(Hospital Universitario de La Princesa), Paola Usán(Universitat de Barcelona), Antonio G. Garcı́a(Universidad Complutense de Madrid), Concepción Pérez(Instituto de Química Médica), Nuria E. Campillo(Centro de Investigaciones Biológicas Margarita Salas), Juan A. Páez(Consejo Superior de Investigaciones Científicas), Esther García‐Palomero(Universitat de Barcelona)
Cited by 160
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293